Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Bachem Holding AG ( (CH:BANB) ) has provided an announcement.
Bachem Holding AG announced the proposal of Dr. Simone Wyss Fedele, CEO of Switzerland Global Enterprise, for election as a new member of its Board of Directors at the upcoming General Meeting in April 2025. Dr. Fedele brings extensive experience in the life sciences industry and international trade, having held leadership roles at Novartis and Takeda Pharmaceuticals. Her addition is expected to enhance Bachem’s strategic positioning and strengthen its board with her international expertise and connections.
More about Bachem Holding AG
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. It provides pharmaceutical and biotech companies worldwide with products for research, clinical development, and commercial application. Headquartered in Switzerland, Bachem operates internationally with locations in Europe, the USA, and Asia, and is listed on the SIX Swiss Exchange.
YTD Price Performance: -12.20%
Average Trading Volume: 20,269
Technical Sentiment Signal: Strong Buy
Current Market Cap: CHF3.87B
For a thorough assessment of BANB stock, go to TipRanks’ Stock Analysis page.